|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.91 CNY | -0.96% |
|
-2.11% | +0.67% |
| May. 07 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
| Apr. 29 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mabwell (Shanghai) Bioscience Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 99.51 million compared to CNY 20.42 million a year ago. Net loss was CNY 673.29 million compared to CNY 692.42 million a year ago.
Basic loss per share from continuing operations was CNY 1.68 compared to CNY 1.73 a year ago. Diluted loss per share from continuing operations was CNY 1.68 compared to CNY 1.73 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.67% | 1.83B | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. 
